Role of MRP4 and MRP5 in biology and chemotherapy

AAPS Journal

Volumn 4, Issue 3, 2002, Pages

  Sampath, Janardhan ^a   Adachi, Masashi ^a   Hatse, Sigrid ^b   Naesens, Lieve ^b   Balzarini, Jan ^b   Flatley, Robin ^c   Matherly, Larry ^c   Schuetz, John ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Cyclic Nucleotides; MRP4; MRP5; Physiology; Transporters

Indexed keywords

EID: 52449097584     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Plagemann PGW. Transport, phosphorylation, and toxicity of a tricyclic nucleoside in cultured Novikoff rat hepatoma cells and other cell lines and release of its monophosphate by the cells. J Natl Cancer Inst. 1976;57(6):1283-1295.
2. Plagemann PGW, Erbe J. Exit transport of a cyclic nucleotide from mouse L-cells. J Biol Chem. 1977;252(6):2010-2016.
3. Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol. 1995;26(7):1469-1475.
4. Frick LW, Nelson DJ, St. Clair MH, Furman PA, and Krenitsky TA. Effects of 3′-azidothymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Comm. 1988;154:124-129.
5. Fridland A, Connelly MC, Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido 3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol. 1990;37(5):665-670.
6. Hall ET, Van JP, Melancon P, Kuchta RD. 3′-Azido-3′-deoxythymidine potently inhibits protein glycosylation: a novel mechanism for AZT cytotoxicity. J Biol Chem. 1994;269(20):14355-14358.
7. Tornevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol. 1995;49(6):829-837.
8. Hatse S, de Clercq E, Balzarini J. Impact of 9-(2-phosphonylmethoxyethyl) adenine on (deoxy) ribonucleotide metabolism and nucleic acid synthesis in tumor cells. FEBS Lett. 1999;445:92-97.
9. Robbins BL, Connelly MC, Marshal DR, Srinivas RV, Fridland, A. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl) adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol. 1995;47:391-397.
10. Hatse S, de Clercq E, Balzarini J. Enhanced 9-(2-phosphonylmethoxyethyl) adenine secretion by a specific, indomethacin-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl) adenine-resistant human erythroleukemia K562 cell line. Mol Pharmacol. 1998;54:907-917.
11. Butcher RW, Robison GA, Hardman JG, Sutherland EW. The role of cyclic AMP in hormone actions. Adv Enzyme Regul. 1968;6:357-389.
12. Newell PC. Signal transduction and motility of Dictyostelium. Biosci Rep. 1995;15(6):445-462.
13. Morrill GA, Doi K, Erlichman J, Kostellow AB. Cyclic AMP binding to the amphibian oocyte plasma membrane: possible interrelationship between meiotic arrest and membrane fluidity. Biochim Biophys Acta.1993;1158:146-154.
14. Maller JL, Butcher FR, Krebs EG. Early effect of progesterone on levels of cyclic Adenosine 3′, 5′-monophosphate in Xenopus oocytes. J Biol Chem. 1979;254(3):579-582.
15. Schorderet-Slatkine S, Schorderet M, Baulieu EE. Cyclic AMP-mediated control of meiosis: effects of progesterone, cholera toxin, and membrane-active drugs in Xenopus laevis oocytes. Proc Natl Acad Sci U S A. 1982;79:850-854.
16. Abell CW, Monahan TM. The role of adenosine 3′, 5′-cyclic monophosphate in the regulation of mammalian cell division. J Cell Biol. 1973;59(3):549-558.
17. Pastan IH, Johnson GS, Anderson WB. Role of cyclic nucleotides in growth control. Ann Rev Biochem. 1975;44:491-522.
18. Wang T, Sheppard JR, Foker JE. Rise and fall of cyclic AMP required for onset of lymphocyte DNA synthesis. Science. 1978;201:155-157.
19. Kaminsky NI, Broadus AE, Hardman JG, et al. Effects of parathyroid hormone on plasma and urinary adenosine 3′, 5′-monophosphate in man. J Clin Invest. 1970;49(12):2387-2395.
20. Kuster J, Zapf J, Jakob A. Effects of hormones on cyclic AMP release in perfused rat livers. FEBS Lett. 1973;32(1):73-77.
21. Zumstein P, Zapf J, Froesch ER. Effects of hormones on cyclic AMP release from rat adipose tissue in vitro. FEBS Lett. 1974;49(1):65-69.
22. O'Brien JA, Strange RC. The release of adenosine 3′,5′-cyclic monophosphate from the isolated perfused rat heart. Biochem J. 1975;152(2):429-432.
23. Cramer H, Lindl T. Release of cyclic AMP from rat superior cervical ganglia after stimulation of synthesis in vitro. Nature. 1974;249(455):380-382.
24. Brunton LL, Buss JE. Export of cyclic AMP by mammalian reticulocytes. J Cyclic Nucl Res. 1980;6(5):369-377.
25. Barber R, Ray KP, Butcher RW. Turnover of adenosine 3′, 5′-monophosphate in WI-38 cultured fibroblasts. Biochemistry. 1980;19(12):2560-2567.
26. Barber R, Butcher RW. The quantitative relationship between intracellular concentration and egress of cyclic AMP from cultured cells. Mol Pharmacol. 1981;19(1):38-43.
27. Fehr TF, Dickinson ES, Goldman SJ, Slakey LL. Cyclic AMP efflux is regulated by occupancy of the adenosine receptor in pig aortic smooth muscle cells. J Biol Chem. 1990;265(19):10974-10980.
28. Ahlstrom M, Lamberg-Allardt C. Regulation of adenosine 3′,5′-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblast like cells: role of cAMP-phosphodiesterase and cAMP efflux. Biochem Pharmacol. 1999;58:1335-1340.
29. Brunton LL, Mayer SE. Extrusion of cyclic AMP from pigeon erythrocytes. J Biol Chem. 1979; 254(19):9714-9720.
30. Boxer LA, Allen JM, Baehner RL. Diminished polymorphonuclear leukocyte adherence: function dependent on release of cyclic AMP by endothelial cells after stimulation of beta-receptors by epinephrine. J Clin Invest. 1980;66(2):268-274.
31. Henderson GB, Strauss BP. Evidence for cAMP and cholate extrusion in C6 rat glioma cells by a common anion efflux pump. J Biol Chem. 1991;266(3):1641-1645.
32. Kapoor CL, Krishna G. Hormone-induced cyclic guanosine monophosphate secretion from guinea pig pancreatic lobules. Science. 1977;196(4293):1003-1005.
33. Tjornhammar ML, Lazaridis G, Bartfai T. Cyclic GMP efflux from liver slices. J Biol Chem. 1983; 258(11):6882-6886.
34. Tjornhammar ML, Lazaridis G, Bartfai T. Efflux of cyclic guanosine 3′, 5′-monophosphate from cerebellar slices stimulated by L-glutamate or high K+ or N-methyl-N′-nitro-N-nitrosoguanidine. Neurosci Lett. 1986;68(1):95-99.
35. Hamet P, Pang SC, Tremblay J. Atrial natriuretic factor-induced egression of cyclic guanosine 3′, 5′-monophosphate in cultured vascular smooth muscle and endothelial cells. J Biol Chem. 1989;264(21):12364-12369.
36. Flo K, Hansen M, Orbo A, Kjorstad KE, Maltau JM, Sager G. Effect of probenecid, verapamil and progesterone on the concentration-dependent and temperature-sensitive human erythrocyte uptake and export of guanosine 3′, 5′ cyclic monophosphate (cGMP). Scand J Clin Lab Invest. 1995; 55(8):715-721.
37. Schultz C, Vaskinn S, Kildalsen H, Sager G. Cyclic AMP stimulates the cyclic GMP egression pump in human erythrocytes: effects of probenecid, verapamil, progesterone, theophylline, IBMX, forskolin, and cyclic AMP on cyclic GMP uptake and association to inside-out vesicles. Biochemistry. 1998;37(4):1161-1166.
38. Boadu E, Sager G. Binding characterization of a putative cGMP transporter in the cell membrane of human erythrocytes. Biochemistry. 1997;36:10954-10958.
39. Patel MJ, Wypij DM, Rose DA, Rimele TJ, Wiseman JS. Secretion of cyclic GMP by cultured epithelial and fibroblast cell lines in response to nitric oxide. J Pharm Exp Therap. 1995;273:16-25.
40. Billiar TR, Curran RD, Harbrecht BG, et al. Association between synthesis and release of cGMP and nitric oxide biosynthesis by hepatocytes. Am J Physiol. 1992;262:C1077:82.
41. Doore J, Bashor MM, Spitzer N, Mawe EC, Saier MH. Regulation of adenosine 3′:5′-monophosphate efflux from glioma cells in culture. J Biol Chem. 1975;250:4371-4371.
42. Rindler MJ, Bashor MM, Spitzer N, Saier MH. Regulation of adenosine 3′:5′-monophosphate efflux from animal cells. J Biol Chem. 1978;253:5431-5436.
43. Finnegan RB, Carey GB. Characterization of cyclic AMP efflux from swine adipocytes in vitro. Obesity Res. 1998;6(4):292-298.
44. Campbell IL, Taylor KW. The effect of metabolites, papaverine, and probenecid on cyclic AMP efflux from isolated rat Islets of Langerhans. Biochim Biophys Acta. 1981;676(3):357-364.
45. Henderson GB, Tsuji JM. Methotrexate efflux in L1210 cells: kinetic and specificity properties of the efflux system sensitive to bromosulfophthalein and its possible identity with a system which mediates the efflux of 3′, 5′-cyclicAMP. J Biol Chem. 1987;262(28):13571-13578.
46. Gogel E, Halloran BP, Strewler GJ. Probenecid inhibits the secretion of nephrogenous adenosine 3′, 5′-monophosphate in normal man. J Clin Endocrinol Metab. 1983;57:689-693.
47. Heasley LE, Brunton LL. Prostaglandin A1 metabolism and inhibition of cyclic AMP extrusion by avian erythrocytes. J Biol Chem. 1985;260(21):11514-11519.
48. Heasley LE, Watson MJ, Brunton LL. Putative inhibitor of cyclic AMP efflux: chromatography, amino acid composition, and identification as a prostaglandin A1-glutathione adduct. J Biol Chem. 1985;260(21):11520-11523.
49. Heasley LE, Azari J, Brunton LL. Export of cyclic AMP from avian red cells: independence from major membrane transporters and specific inhibition by prostaglandin A1. Mol Pharmacol. 1985; 27(1):60-65.
50. Coulson R, Baranaik J, Stec WJ, Jastriff B. Transport and metabolism of N6- and CS-substituted analogs of adenosine 3′, 5′-monophosphate and adenosine 3′, 5′-cyclicphophorothioate by the isolated perfused rat kidney. Life Sci. 1983;32:1489-1498.
51. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57:3537-3547.
52. Mccr M. 51 Human ATP-Binding Cassette Transporters. Available at: http://humanabc.4t.com/humanabc.htm. Accessed: April 11, 2002.
53. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochem Biophys Acta. 1999;1461(2):347-357.
54. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the Multidrug Resistance-associated Proteins. J Natl Cancer Inst. 2000;92(16):1295-1302.
55. Schuetz JD, Connelly MC, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999;5(9):1048-1051.
56. Lee K, Klein-Szanto AJP, Kruh GD. Analysis of the MRP4 drug resistant profile in transfected NIH3T3. J Natl Cancer Inst. 2000;92(23):1934-1940.
57. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradial 17-beta-D-glucoronide by multidrug resistance protein 4: resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001;276(36):33747-33754.
58. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA. 2000;97(13):7476-7481.
59. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000;275(39):30069-30074.
60. Shoshani I, Laux WH, Perigaud C, Gosselin G, Johnson RA. Inhibition of adenylyl cyclase by acyclic nucleoside phosphonate antiviral agents. J Biol Chem. 1999;274:34742-34744.
61. Schuetz EG, Strom S, Yasuda K, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters and cytochrome P450. J Biol Chem 2001;276(42):39411-39418.
62. Sinai CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731-744.